Eupi 40 mg/vial (IV Injection)
40 mg vial: ৳ 80.00
Medicine Details
Category | Details |
---|---|
Generic | Omeprazole |
Company | Pharmasia limited |
Also available as |
Indications
- Gastric and duodenal ulcer
- NSAID-associated duodenal and gastric ulcer
- As prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
- Gastro-esophageal reflux disease
- Long-term management of acid reflux disease
- Acid-related dyspepsia
- Severe ulcerating reflux esophagitis
- Prophylaxis of acid aspiration during general anesthesia
- Zollinger-Ellison syndrome
- Helicobacter pylori-induced peptic ulcer
Pharmacology
- Inhibitor of gastric acid secretion
- Blocker of hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
- Onset of antisecretory effect within one hour
- Maximum effect occurring within two hours
- Inhibition of secretion lasting up to 72 hours
- Gradual return of secretory activity over 3 to 5 days after discontinuation
Dosage
- Oral administration
- Benign gastric and duodenal ulcer dosage regimen
- NSAID-associated duodenal or gastric ulcer dosage regimen
- Gastro-esophageal reflux disease dosage regimen
- Long-term management of acid reflux disease dosage regimen
- Acid-related dyspepsia dosage regimen
- Prophylaxis of acid aspiration dosage regimen
- Zollinger-Ellison syndrome dosage regimen
- Helicobacter pylori eradication regimen in peptic ulcer disease
- Pediatric use in severe ulcerating reflux esophagitis dosage regimen
- IV Injection administration for prophylaxis of acid aspiration, duodenal ulcer, gastric ulcer, or reflux oesophagitis
Administration
- IV Injection direction and reconstitution process
- IV Infusion process and reconstitution
- Use of freshly prepared solution
- Use within specific time frame after reconstitution
- Avoidance of mixing or co-administration with other drugs
Interaction
- Potential impact on ketoconazole absorption
- Metabolism through cytochrome P450 affecting diazepam, phenytoin, and warfarin
- Monitoring and potential dose adjustment for warfarin or phenytoin
- Increased plasma concentrations during concomitant administration with clarithromycin
- No evidence of interaction with phenacetin, theophylline, caffeine, and other substances
- Increased bioavailability of digoxin during simultaneous treatment
- Absorption not affected by alcohol or food
Contraindications
- Known hypersensitivity to omeprazole
- Need for exclusion of malignancy in suspected gastric ulcer before treatment
Side Effects
- Mild and reversible adverse reactions
- Reported skin rash, urticaria, pruritus, photosensitivity, and bullous eruption
- Gastrointestinal reactions such as diarrhea, headache, constipation, and nausea/vomiting
- Neurological reactions including dizziness, somnolence, and paraesthesia
- Potential mental confusion, agitation, and depression in severely ill patients
- Musculoskeletal symptoms and rare instances of vision disturbance, gynaecomastia, and hepatic failure
Pregnancy & Lactation
- No adverse effects indicated on pregnancy or fetal health from epidemiological studies
- Use during pregnancy deemed safe
- No available information on passage into breast milk and effects on neonate
Precautions & Warnings
- Avoid concomitant use with clopidogrel
- Potential association with increased risk for osteoporosis-related fractures
- Atrophic gastritis noted in long-term treatment
Therapeutic Class
- Proton Pump Inhibitor
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children